Newsletter July 2023 No.216
Top News
On May 25, 2023, the "Pharmaceutical Association of Japan Press Conference" was held at Bellesalle Iidabashi Station (Chiyoda-ku, Tokyo). At the press conference, newly elected Chairman Hiroaki Ueno made a statement of policy at the 268th Pharmaceutical Manufacturers Association of Japan (PMAJ) General Meeting held on the same day, and under the title of "Toward a Nation Driven by Innovation," discussed the challenging environment facing the pharmaceutical industry and the PMAJ's future focus. The press conference was held in a hybrid format of on-site and online, with 29 members of the press from 22 companies in attendance and a lively Q&A session, indicating a high level of interest in the future direction of the pharmaceutical industry. The following is a summary of Chairman Ueno's presentation and the Q&A session.
Topics
- The 12th Asian Pharmaceutical Association Collaboration Conference (APAC) - Bringing Innovative Medicines to the People of Asia Quickly
- Joint Symposium with the Joint Meeting of the Japanese Society of Infectious Diseases/Japanese Society of Chemotherapy" was held.
Bringing Antimicrobial Agents from Japan to the World Again! Building a Drug Discovery Ecosystem through Industry-Academia-Government Collaboration - The Pharmaceutical Manufacturers Association of Japan (PMAJ) held a media forum on "What to do about Vaccines? -What can we do now for the future?
- The Pharmaceutical Manufacturers Association of Japan (PMAJ) Media Forum on Health and the Economy "The Future of Health Economics Research in Japan's Aging Society, a Global Focus
- The "Joint General Meeting of the Drug Evaluation Committee and the Pharmaceutical Affairs Committee in 2023" was held.
Policy Research Institute page
Trends in medical record integration as seen in the case of COVID-19
From JPMA
On assuming the office of Chairman - Aiming for a country where innovation is dynamic